University of Pennsylvania

ScholarlyCommons
CPHI Data Briefs

Center for Public Health Initiatives

1-2018

Supervised Injection Facilities
Ruth Shefner
University of Pennsylvania

Colleen McGrath
University of Pennsylvania

Meghana Sharma
University of Pennsylvania

Evan Anderson
University of Pennsylvania

Benjamin Cocchiaro
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/publichealth_databriefs
Part of the Public Health Commons

Recommended Citation
Shefner, Ruth; McGrath, Colleen; Sharma, Meghana; Anderson, Evan; and Cocchiaro, Benjamin,
"Supervised Injection Facilities" (2018). CPHI Data Briefs. 3.
https://repository.upenn.edu/publichealth_databriefs/3

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/publichealth_databriefs/3
For more information, please contact repository@pobox.upenn.edu.

Supervised Injection Facilities
Abstract
Injection drug use once accounted for half of the new HIV cases each year in Philadelphia. Today, it
accounts for less than 6%. This achievement is the result, in large part, of increased access to sterile
syringes through needle exchange at Prevention Point Philadelphia. But while tremendous strides have
been made in reducing the HIV risk for people who inject drugs (PWID), the story with respect to skin and
soft tissue infection (SSTI) and overdose is grim. SSTIs are life-threatening, painful, and remain common
among PWID. Rates of fatal overdose, meanwhile, have skyrocketed in recent years, resulting in 907
deaths in 2016 and over 1200 in 2017. Trends for injection-related HIV and injection-related infection and
overdose have taken different trajectories because access to sterile injection materials only addresses a
portion of the risk environment for injection drug use. Avoiding SSTIs is hard, even with a sterile syringe,
when injecting in poorly lit, cold, dirty or otherwise unhygienic spaces.
Reversing an overdose is possible with naloxone, but there has to be someone to administer it, and PWID
often inject in secluded spaces. Some evidence also suggests that overdose is more likely when PWID
inject hurriedly – from fear of assault or arrest – and without the opportunity to taste and control dosing.
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BACKGROUND
Injection drug use once accounted for
half of the new HIV cases each year in
Philadelphia. Today, it accounts for less
than 6%1. This achievement is the result,
in large part, of increased access to
sterile syringes through needle exchange
at Prevention Point Philadelphia. But
while tremendous strides have been
made in reducing the HIV risk for people
who inject drugs (PWID), the story with
respect to skin and soft tissue infection
(SSTI) and overdose is grim. SSTIs are
life-threatening, painful, and remain
common among PWID2. Rates of fatal
overdose, meanwhile, have skyrocketed
in recent years, resulting in 907 deaths in
2016 and over 1200 in 2017.
Trends for injection-related HIV and
injection-related infection and overdose
have taken different trajectories because
access to sterile injection materials

only addresses a portion of the risk
environment for injection drug use3.
Avoiding SSTIs is hard, even with a sterile
syringe, when injecting in poorly lit, cold,
dirty or otherwise unhygienic spaces.
Reversing an overdose is possible with
naloxone, but there has to be someone
to administer it, and PWID often inject
in secluded spaces. Some evidence also
suggests that overdose is more likely
when PWID inject hurriedly – from fear
of assault or arrest – and without the
opportunity to taste and control dosing4.

SIF: A HARM REDUCTION
APPROACH
Supervised Injection Facilities (SIFs)
provide hygienic spaces and clinical
supervision for injection drug use.
Supervising health professionals
advise about injection-related harms,
provide clean injecting supplies, reverse

Figure 1. Insite (Photo: Vancouver Coastal Health)

“Individual and community
harms associated with injecting
drugs are fundamentally
constituted by the fact that many
people who inject drugs lack a
clean, comfortable, and secure
place to inject. Setting aside the
evidence supporting SIFs, which
is abundant, consistent and
positive, providing such a place
just makes sense.”
—CPHI Senior Fellow,
Evan Anderson JD, PhD
overdoses, and provide linkages to
medical and social services. SIFs are
predicated on the harm reduction
principle of meeting people in need
“where they are.” They are especially
valuable, in this regard, for reaching
vulnerable populations. SIFs have existed
for over 3 decades in Europe, and for
over a decade each in Australia and
Canada. There are over 100 facilities in
operation globally.
Insite is North America’s first government
authorized SIF. It opened in 2003 in
Vancouver’s Lower East Side. The facility
provides injection booths (see figure 1)
where clients use pre-obtained drugs
under staff supervision and with free
injection equipment. Staff are available
to reverse overdoses and provide other
healthcare services. Insite offers onsite
detoxification services and long-term
recovery treatment and housing5.
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EVIDENCE SUPPORTING SIFS
Effects on PWID Health:
PWID who use SIFS report less frequent public injection, less syringe sharing, and
more uptake in addiction treatment. Meta-analyses suggest that frequent SIF use is
associated with an almost 70% reduction in syringe sharing. Evidence also suggests
that SIF users are more likely to engage in non-injection-related health behaviour, such
as increased condom use and increased use of medical care and social services.
SIFs also prevent fatal overdose among PWID. Since Insite opened in 2003, there has
not been a single fatal overdose at the facility, and overdose rates have declined 35%
around the facility and 9% city-wide5. Similar findings have been reported at SIFs
elsewhere.

Effects on Community Health:
SIFs have well established benefits for community health and order. The opening of
Insite was associated with a significant decrease in public injecting, publicly-discarded
syringes, and injection-related litter. Similar reductions were reported in Australia
and Spain by residents, business owners, and PWID themselves. There is no evidence
that implementing a SIF increases crime; in fact, six studies conducted in Canada and
Australia found no change in public order and safety. A recent study also indicates that
Insite has helped to reduce harmful interactions between PWID and police.

Economic Effects:
The economic case for SIFs is substantial. Start-up and operating costs are small
compared to the cost of providing reactive care for PWID with otherwise unmet needs.
Medical referral services available at Insite were associated with a substantial decrease
in hospital length of stay; decreased HIV transmission rates alone save health systems
as much as $6,000,000 CAD per year, an incremental cost-effectiveness ratio of $10,763
CAD per DAY6.

Obstacles and Opportunities:
There are no officially sanctioned facilities currently operating in the U.S. However,
there are some unsanctioned facilities, and Boston has adopted a Supportive Place for
Observation and Treatment (SPOT) that offers “engagement, support, [and] medical
monitoring” for “8-10 individuals at a time who are over-sedated from the use of
substances”7. Evaluations of these facilities are just emerging. A number of other cities,
including Seattle, are actively planning to open a SIF8.
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There are potential impediments. Federal
law enforcement could challenge a SIF
under a law that prohibits maintaining a
space for the use of illicit drugs, although
there are reasonable arguments that
this law does not apply to a SIF. There
are political “NIMBY-ism” challenges,
too. Mobilizing community support and
building coalitions across health, law
enforcement and other stakeholders
has been essential to successful
implementation in other places.
Despite these challenges, the public
health arguments supporting the
implementation of a SIF are growing. The
Mayor’s Task Force to Combat the Opioid
Epidemic recommended exploring the
creation of a SIF last year9. The city has
since sent health and law enforcement
officials to Insite. Given Governor Wolf’s
declaration that opioid use is a “disaster
emergency” last week, the time for bold
action has never been clearer.

Conclusion:
Opening an SIF is an essential
component of a broader strategy to
reduce injection-related harms, including
overdose.
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